The BRAF mutation was identified in 64 primary tumours (9.6%) of different origins with various frequencies, with particularly high frequency in prostatic carcinoma (PC) (20/25, 80%) and urothelial carcinoma (30/45, 67%) tissue samples. This evidence concerns the gene BRAF and urothelial carcinoma.